Theranostic radioimmunotherapy (RIT) combined with immunotherapy : The best way to go ? Jean-François Chatal*, Med Res Innov, 2017 doi : 10.15761/MRI.1000119

Barbet J, Arlicot N, Gaugler MH, Chérel M, Guilloteau D, Kraeber-Bodéré F. Editorial : Innovative Radiopharmaceuticals in Oncology and Neurology. Front Med (Lausanne). 2017 Jan 11 ;3:74. doi : 10.3389/fmed.2016.00074. eCollection 2016.

Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma. C. Bailly et al. (accpeté pour publication dans Oncotarget)

“Immuno-PET for Clinical Theranostic Approaches« . Clément Bailly, Pierre-François Cléry, Alain Faivre-Chauvet, Mickaël Bourgeois, François Guérard, Ferid Haddad, Jacques Barbet, Michel Chérel, Françoise Kraeber-Bodéré, Thomas Carlier and Caroline Bodet-Milin. International Journal of Molecular Sciences 2017, 18 (1), 57 2017

Bailly C, Bodet-Milin C, Rousseau C, Faivre-Chauvet A, Kraeber-Bodéré F, Barbet J. EJNMMI radiopharm. chem. (2017) 2 : 6. https://doi.org/10.1186/s41181-017-0026-8

van Leeuwen FWB, Cornelissen B, Caobelli F, Evangelista L, Rbah-Vidal L, Del Vecchio S, Xavier C, Barbet J, de Jong M. EJNMMI radiopharm. chem. (2017) 2 : 15. https://doi.org/10.1186/s41181-017-0034-8

Bourgeois M, Bailly C, Guerard F, Cherel M, Faivre-Chauvet A, Kraeber-Bodere F, Bodet-Milin C. Radioimmunoconjugates for treating cancer : recent advances and current opportunities. Expert Opin Biol Ther 2017, 4 : 1-7 IF 3.684

Frindel M, Le Saëc P, Beyler M, Navarro AS, Saï-Maurel C, Alliot C, Chérel M, Gestin JF, Faivre-Chauvet A, Tripier R. Cyclam te1pa for 64Cu PET imaging. Bioconjugation to antibody, radiolabeling and preclinical application in xenografted colorectal cancer. RSC Adv. 2017, 7 : 9272 IF 3.108

Jamet B, Carlier T, Campion L, Bompas E, Girault S, Borrely F, Ferrer L, Rousseau M, Venel Y, Kraeber-Bodéré F, Rousseau C. Initial FDG-PET/CT predicts survival in adults ewing sarcoma family of tumors Oncotarget 2017, 8:77050-77060 IF 5.168